Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jiangya Tongmai Formula in H-type Hypertension with Carotid Atherosclerosis
ChiCTR2300070509Phase 3Not yet recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Jul 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN), carotid atheroma (CAS) and hyperhomocysteinemia comparing Jiangya Tongmai Formula with Placebo (2 arms). Primary endpoints: Endothelial function and Inflammatory factors. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
Jiangya Tongmai Formula
03
Conditions
hypertension (HTN)carotid atheroma (CAS)hyperhomocysteinemia
Beyond the preview
Go deeper on ChiCTR2300070509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070509.